United States, No... Preferred Partner "New technology, new product, FDA approval 11-98. In-office diagnostic instrument provides quick, non-invasive, inexpensive test for pathogens implicated in heart disease, stroke, and premature births. Product is in production and has had limited sales in US and Europe. Dealer network in place. Management team in place. All efforts heretofore focused on regulatory approval and refining production processes. Now seeking equity funding for nationwide product launch. Marketing to concentrate on clinicians wanting early diagnostic information in a high margin test. Company success based on disposable test probe tips. Projected $75M revenues within 5 years. Anticipated liquidity event (IPO or merger) within three ye...